Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass
- 31 March 2004
- journal article
- clinical trial
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 77 (3) , 942-949
- https://doi.org/10.1016/j.athoracsur.2003.08.054
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Pathophysiology, Clinical Manifestations, and Prevention of Ischemia-Reperfusion InjuryAnesthesiology, 2001
- Role of the Complement System in Ischaemic Heart DiseaseBioDrugs, 2001
- Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary BypassCirculation, 1999
- Myocardial Infarction and Apoptosis After Myocardial Ischemia and ReperfusionCirculation, 1998
- The Systemic Inflammatory Response to Cardiopulmonary BypassAnesthesia & Analgesia, 1997
- Inhibition of complement activity by humanized anti-C5 antibody and single-chain FvMolecular Immunology, 1996
- Methodology of serial ECG classification using an adaptation of the NOVACODE for Q wave myocardial infarction in the bypass angioplasty revascularization investigation (BARI)Journal of Electrocardiology, 1996
- Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.Journal of Clinical Investigation, 1995
- Complement activation during cardiopulmonary bypass in infants and childrenThe Journal of Thoracic and Cardiovascular Surgery, 1993
- Cardiopulmonary bypass induces leukocyte-platelet adhesionBlood, 1992